Analysts See 15% Gains Ahead For The Holdings of FXH
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 15 2024
0mins
Should l Buy OGN?
Source: NASDAQ.COM
ETF Analyst Target Price Insights: The First Trust Health Care AlphaDEX Fund ETF (FXH) has an implied analyst target price of $126.39, indicating a potential upside of 14.54% from its current trading price of $110.35.
Individual Stock Upside Potential: Notable underlying holdings such as Intra-Cellular Therapies Inc (ITCI), DENTSPLY SIRONA Inc (XRAY), and Organon & Co (OGN) show significant upside potential, with expected increases of 30.64%, 27.52%, and 19.97% respectively based on their average analyst target prices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OGN
Wall Street analysts forecast OGN stock price to rise
5 Analyst Rating
0 Buy
1 Hold
4 Sell
Strong Sell
Current: 7.060
Low
5.00
Averages
8.50
High
12.00
Current: 7.060
Low
5.00
Averages
8.50
High
12.00
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Atopic Dermatitis Market Growth Insights
- Market Size Growth: The atopic dermatitis treatment market is expected to continue growing positively by 2034, with the United States holding the largest market share, reflecting strong demand for new therapies that drive overall market expansion.
- Introduction of New Therapies: The launch of new therapies such as Rocatinlimab and Amlitelimab is anticipated to transform the market landscape by providing more effective treatment options to meet the increasing patient demand.
- Rising Patient Numbers: In 2024, approximately 53 million diagnosed cases of atopic dermatitis are expected in the 7MM, with the increase in patient numbers directly fueling the demand for advanced treatment options and promoting market growth.
- Changing Competitive Landscape: As new drugs undergo clinical trials and enter the market, competition will intensify, particularly with companies like Eli Lilly leveraging their product portfolios to capture significant market share in the EU4 and Japan, showcasing strong market potential.
See More
Organon & Co. Reports Q4 2025 Earnings Insights
- Financial Performance Overview: In 2025, Organon reported $6.2 billion in revenue and $1.9 billion in adjusted EBITDA, despite a 3% year-over-year revenue decline, indicating pressure in a competitive market landscape.
- Product Line Challenges: Sales of Nexplanon decreased by 20% in Q4 and 4% for the full year, reflecting the impact of U.S. policy changes and competitive pressures on women's health products, leading to an overall business downturn.
- Strategic Adjustments: The company opted to lower its dividend payout ratio, reallocating funds for debt reduction, and generated approximately $390 million in net proceeds from the divestiture of the Jada system to enhance financial flexibility.
- Future Outlook: Management anticipates that revenue and adjusted EBITDA for 2026 will align with 2025 figures at $6.2 billion and $1.9 billion, respectively, despite ongoing market challenges and margin pressures.
See More
Organon Stock Drops 13% Following Disappointing Q4 Earnings
- Organon Shares Fall: Organon shares experienced a 13% decline following the announcement of a profit miss in the fourth quarter.
- Impact of Earnings Report: The disappointing earnings report has raised concerns among investors regarding the company's financial performance and future outlook.
- Market Reaction: The significant drop in share price reflects investor sentiment and market reaction to the missed profit expectations.
- Future Projections: Analysts are now closely monitoring Organon's strategies and projections to assess potential recovery and growth opportunities.
See More
Organon Q4 Financials Miss Expectations, Shares Drop
- Disappointing Financials: Organon's Q4 adjusted EPS of $0.63 and revenue of $1.5B represent approximately 30% and 5% year-over-year declines, respectively, missing consensus estimates of $0.73 and $1.53B, indicating significant financial pressure on the company.
- Women's Health Segment Decline: The Women's Health unit generated $398M in revenue, reflecting a 15% drop year-over-year, marking the second consecutive quarter of decline, primarily due to policy-related demand headwinds in the U.S. and a $17M sales hit from Nexplanon contraceptive implant.
- Biosimilars Growth: Despite overall poor performance, Organon's biosimilar segment expanded by approximately 11% year-over-year, contributing $181M to the topline, showcasing growth potential in this area amidst broader challenges.
- Cautious Future Outlook: The company projects $6.2B in revenue for 2026, slightly below last year's $6.22B but above analysts' expectations of $6.11B, with adjusted EBITDA expected to reach nearly $1.9B, indicating some growth expectations despite ongoing challenges.
See More
Organon Declares $0.02 Quarterly Dividend in Line with Previous
- Quarterly Dividend Announcement: Organon declares a quarterly dividend of $0.02 per share, consistent with previous distributions, indicating the company's ongoing ability to maintain stable cash flow, although market sentiment regarding its future growth potential remains cautious.
- Dividend Yield: The forward yield of 1.04% reflects the returns provided to shareholders in the current economic environment, despite overall market skepticism about the company's stock performance.
- Shareholder Record Dates: The dividend will be payable on March 12, with a record date of February 23 and an ex-dividend date also on February 23, ensuring shareholders receive timely returns and bolstering investor confidence in the company's stability.
- Financial Performance Overview: Organon's non-GAAP EPS of $0.63 missed expectations by $0.10, while revenue of $1.51 billion met forecasts; however, the women's health unit's poor performance led to a Q4 miss, highlighting challenges in specific business areas.
See More
Organon Reports Q4 Earnings Miss with Cautious Outlook
- Earnings Report: Organon reported a non-GAAP EPS of $0.63, missing expectations by $0.10, indicating pressure on profitability that could undermine investor confidence.
- Revenue Performance: The company achieved $1.51 billion in revenue for Q4, aligning with market expectations; however, the overall performance remains weak, reflecting potential deficiencies in market demand.
- Market Outlook: Organon adopts a cautious outlook ahead of its earnings release, suggesting ongoing challenges, particularly in the highly competitive healthcare sector.
- Analyst Ratings: Seeking Alpha's Quant Rating on Organon reveals market concerns regarding its future performance, potentially prompting investors to reassess their investment strategies.
See More
Atopic Dermatitis Market Growth Insights
- Market Size Growth: The atopic dermatitis treatment market is expected to continue growing positively by 2034, with the United States holding the largest market share, reflecting strong demand for new therapies that drive overall market expansion.
- Introduction of New Therapies: The launch of new therapies such as Rocatinlimab and Amlitelimab is anticipated to transform the market landscape by providing more effective treatment options to meet the increasing patient demand.
- Rising Patient Numbers: In 2024, approximately 53 million diagnosed cases of atopic dermatitis are expected in the 7MM, with the increase in patient numbers directly fueling the demand for advanced treatment options and promoting market growth.
- Changing Competitive Landscape: As new drugs undergo clinical trials and enter the market, competition will intensify, particularly with companies like Eli Lilly leveraging their product portfolios to capture significant market share in the EU4 and Japan, showcasing strong market potential.
See More
Organon & Co. Reports Q4 2025 Earnings Insights
- Financial Performance Overview: In 2025, Organon reported $6.2 billion in revenue and $1.9 billion in adjusted EBITDA, despite a 3% year-over-year revenue decline, indicating pressure in a competitive market landscape.
- Product Line Challenges: Sales of Nexplanon decreased by 20% in Q4 and 4% for the full year, reflecting the impact of U.S. policy changes and competitive pressures on women's health products, leading to an overall business downturn.
- Strategic Adjustments: The company opted to lower its dividend payout ratio, reallocating funds for debt reduction, and generated approximately $390 million in net proceeds from the divestiture of the Jada system to enhance financial flexibility.
- Future Outlook: Management anticipates that revenue and adjusted EBITDA for 2026 will align with 2025 figures at $6.2 billion and $1.9 billion, respectively, despite ongoing market challenges and margin pressures.
See More
Organon Stock Drops 13% Following Disappointing Q4 Earnings
- Organon Shares Fall: Organon shares experienced a 13% decline following the announcement of a profit miss in the fourth quarter.
- Impact of Earnings Report: The disappointing earnings report has raised concerns among investors regarding the company's financial performance and future outlook.
- Market Reaction: The significant drop in share price reflects investor sentiment and market reaction to the missed profit expectations.
- Future Projections: Analysts are now closely monitoring Organon's strategies and projections to assess potential recovery and growth opportunities.
See More
Organon Q4 Financials Miss Expectations, Shares Drop
- Disappointing Financials: Organon's Q4 adjusted EPS of $0.63 and revenue of $1.5B represent approximately 30% and 5% year-over-year declines, respectively, missing consensus estimates of $0.73 and $1.53B, indicating significant financial pressure on the company.
- Women's Health Segment Decline: The Women's Health unit generated $398M in revenue, reflecting a 15% drop year-over-year, marking the second consecutive quarter of decline, primarily due to policy-related demand headwinds in the U.S. and a $17M sales hit from Nexplanon contraceptive implant.
- Biosimilars Growth: Despite overall poor performance, Organon's biosimilar segment expanded by approximately 11% year-over-year, contributing $181M to the topline, showcasing growth potential in this area amidst broader challenges.
- Cautious Future Outlook: The company projects $6.2B in revenue for 2026, slightly below last year's $6.22B but above analysts' expectations of $6.11B, with adjusted EBITDA expected to reach nearly $1.9B, indicating some growth expectations despite ongoing challenges.
See More
Organon Declares $0.02 Quarterly Dividend in Line with Previous
- Quarterly Dividend Announcement: Organon declares a quarterly dividend of $0.02 per share, consistent with previous distributions, indicating the company's ongoing ability to maintain stable cash flow, although market sentiment regarding its future growth potential remains cautious.
- Dividend Yield: The forward yield of 1.04% reflects the returns provided to shareholders in the current economic environment, despite overall market skepticism about the company's stock performance.
- Shareholder Record Dates: The dividend will be payable on March 12, with a record date of February 23 and an ex-dividend date also on February 23, ensuring shareholders receive timely returns and bolstering investor confidence in the company's stability.
- Financial Performance Overview: Organon's non-GAAP EPS of $0.63 missed expectations by $0.10, while revenue of $1.51 billion met forecasts; however, the women's health unit's poor performance led to a Q4 miss, highlighting challenges in specific business areas.
See More
Organon Reports Q4 Earnings Miss with Cautious Outlook
- Earnings Report: Organon reported a non-GAAP EPS of $0.63, missing expectations by $0.10, indicating pressure on profitability that could undermine investor confidence.
- Revenue Performance: The company achieved $1.51 billion in revenue for Q4, aligning with market expectations; however, the overall performance remains weak, reflecting potential deficiencies in market demand.
- Market Outlook: Organon adopts a cautious outlook ahead of its earnings release, suggesting ongoing challenges, particularly in the highly competitive healthcare sector.
- Analyst Ratings: Seeking Alpha's Quant Rating on Organon reveals market concerns regarding its future performance, potentially prompting investors to reassess their investment strategies.
See More
